Media stories about Quest Diagnostics (NYSE:DGX) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quest Diagnostics earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.2956735399358 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Quest Diagnostics (NYSE DGX) traded up 0.13% during mid-day trading on Tuesday, hitting $106.60. 639,442 shares of the stock were exchanged. The company’s 50-day moving average price is $108.63 and its 200 day moving average price is $103.40. Quest Diagnostics has a 52 week low of $79.12 and a 52 week high of $112.96. The firm has a market capitalization of $14.54 billion, a price-to-earnings ratio of 21.48 and a beta of 0.69.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.13. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same period in the previous year, the company earned $1.34 EPS. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Equities research analysts expect that Quest Diagnostics will post $5.69 EPS for the current year.

Several analysts have issued reports on the stock. UBS AG restated a “buy” rating and set a $115.00 price target (up from $102.00) on shares of Quest Diagnostics in a research report on Tuesday, April 25th. Evercore ISI restated an “in-line” rating and set a $104.50 price target on shares of Quest Diagnostics in a research report on Wednesday, June 28th. Barclays PLC restated a “hold” rating and set a $110.00 price target on shares of Quest Diagnostics in a research report on Wednesday, July 19th. BidaskClub upgraded shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Mizuho upped their price target on shares of Quest Diagnostics from $115.00 to $122.00 and gave the company a “buy” rating in a research report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $109.62.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/quest-diagnostics-dgx-given-daily-news-sentiment-rating-of-0-12/1492650.html.

In related news, Director Jeffrey M. Leiden sold 296 shares of Quest Diagnostics stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $106.66, for a total transaction of $31,571.36. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $639,960. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey M. Leiden sold 1,304 shares of Quest Diagnostics stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $108.73, for a total transaction of $141,783.92. Following the transaction, the director now directly owns 6,296 shares of the company’s stock, valued at $684,564.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,362 shares of company stock valued at $6,600,758. 1.50% of the stock is owned by corporate insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.